natgillin/translations-raw huggingface dataset:
Additionally, other adverse reactions reported with post-marketing use of M-M-RVAXPRO and/or in clinical studies and post-marketing use of previous formulations of monovalent and of the combined measles, mumps, and rubella vaccines manufactured by Merck & Co., Inc. without regard to causality or frequency are available and are summarised in section b (frequency not known).
Osim toga, druge nuspojave prijavljene nakon stavljanja cjepiva M-M-RVAXPRO u promet i/ili tijekom kliničkih ispitivanja i nakon stavljanja u promet prethodnih monovalentnih i kombiniranih cjepiva protiv morbila, parotitisa i rubele proizvođača Merck & Co., Inc., bez obzira na njihovu uzročno-posljedičnu povezanost ili učestalost navedene su u dijelu b (učestalost nepoznato).
Additionally, patients have to drink 1-2 glasses of fluid before bedtime regardless of perceived thirst and replenish fluids overnight with each episode of nocturia.
Osim toga, bolesnici trebaju popiti 1-2 čaše tekućine prije spavanja bez obzira na osjećaj žeđi, a zasvaku epizodu nikturije tijekom noći popiti još tekućine.
Additionally, patients treated with this medicine and ribavirin combination therapy and zidovudine could be at increased risk of developing anaemia (low number of red blood cells).
Osim toga, bolesnici koji se liječe ovim lijekom u kombinaciji s ribavirinom, a i uzimaju zidovudin mogu imati povećan rizik za razvoj anemije (smanjen broj crvenih krvnih stanica).
Additionally, prescribers and pharmacists will be informed via a specific letter regarding the timelines for removing EXJADE dispersible tablets from the EU market.
Uz to, liječnici propisivači i ljekarnici će putem posebnog dopisa biti obaviješteni o vremenskim okvirima za uklanjanje EXJADE tableta za oralnu suspenziju s EU tržišta.
Additionally, pretreatment with antihistamines and/or antipyretics prior to LEMTRADA administration may also be considered.
Osim toga, može se razmotriti i premedikacija antihistaminicima i/ili antipireticima prije primjene lijeka LEMTRADA.
Additionally, randomised, double-blind, placebo-controlled, crossover drug-drug interaction studies with ibuprofen, diclofenac and valproate were performed in healthy subjects and are summarised in section 4.5.
Osim toga, provedena su randomizirana, dvostruko slijepa, placebom kontrolirana ukrižena ispitivanja lijek-lijek interakcija s ibuprofenom, diklofenakom i valproatom u zdravih ispitanika te je sažetak naveden u dijelu 4.5.
Additionally, ribavirin or Pegasys plus ribavirin combination therapy can be discontinued.
Dodatno se može prekinuti primjena ribavirina ili kombinirana terapija lijekom Pegasys i ribavirinom.
Additionally, studies have not been conducted to assess the effects of discontinuing or reducing the recommended dose of Enbrel following its long-term use in patients with JIA.
Nadalje, nisu provedena ni ispitivanja kojima bi se procijenili učinci prekida primjene ili smanjenja preporučene doze Enbrela nakon dugotrajne primjene bolesnika s JIA.
Additionally, the Committee considered that since Ravicti is available as a liquid this could make the medicine more palatable especially for children, compared with other medicines available as granules to be added to food; the liquid formulation also facilitates its administration via tube to patients unable to swallow because of neurological problems.
Osim toga, Odbor smatra da bi, uzevši u obzir da je Ravicti dostupan u obliku tekućine, to moglo učiniti lijek ukusnijim, posebice za djecu, u usporedbi s drugim lijekovima koji su dostupni u obliku granula koje se dodaju u hranu; tekući pripravci također olakšavaju davanje lijeka s pomoću cjevčica za pacijente koji ne mogu gutati zbog neuroloških problema.
Additionally, the company that markets Sylvant is required to set up a patient registry to provide further data on long-term safety.
Nadalje, od tvrtke koja stavlja u promet lijek Sylvant zatraženo je da uspostavi registar bolesnika kako bi dostavila podatke o dugoročnoj sigurnosti.
Additionally, the efficacy and safety of abacavir given once daily has been demonstrated in a pivotal clinical study (CNA30021- See section 5.1 Clinical experience).
Osim toga, djelotvornost i sigurnost abakavira primijenjenog jedanput na dan dokazana je i u pivotalnoj kliničkoj studiji (CNA30021- vidjeti dio 5.1 Kliničko iskustvo).
Additionally, the efficacy and safety of abacavir given once daily has been demonstrated in a pivotal clinical study (CNA30021- See section 5.1 Clinical experience).
Osim toga, djelotvornost i sigurnost abakavira primijenjenog jedanput na dan dokazana je i u pivotalnoj kliničkoj studiji (CNA30021- vidjeti dio 5.1.Kliničko iskustvo).
Additionally, the geometric mean plasma AUCinf of free (non-liposome associated) MTP-PE in mild and moderate hepatic impairment were 47% higher than the corresponding values in the matched normal hepatic function groups.
Dodatno, geometrijska srednja vrijednost plazmatskog AUCinf slobodnog (ne- liposomalnog) MTP-PE kod blagog i umjerenog oštećenja jetre bila je 47% viša od odgovarajućih vrijednosti u skupini s normalnom funkcijom jetre.
Additionally, the observed incidence of antibody (including inhibitory antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.
Osim toga, na opaženu incidenciju pozitivnih nalaza protutijela (uključujući inhibicijska protutijela) može utjecati nekoliko čimbenika, uključujući metodologiju testiranja, rukovanje uzorkom, vrijeme prikupljanja uzorka, istodobno primijenjeni lijekovi te osnovna bolest.
Additionally, the overall number of deaths occurring in field conditions amongst piglets born to vaccinated sows and gilts was investigated and compared with those born to unvaccinated mothers.
Nadalje, ukupan broj smrtnih slučajeva u uvjetima na terenu u prasadi oprašene od cijepljenih krmača i nazimica istražen je i ispitan u usporedbi s brojem prasadi oprašene od necijepljenih ženki svinja.
Additionally, the pack contains:
Osim toga, pakiranje sadrži:
Additionally, the pharmacokinetics of Enbrel in rheumatoid arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.
Nadalje, farmakokinetika Enbrela kod bolesnika s reumatoidnim artritisom, ankilozantnim spondilitisom i plak psorijazom je slična.
Additionally, the systemic exposures (AUCinf) of free (non-liposome associated) MTP-PE in mild or moderate renal insufficiency were similar to those observed in healthy adult subjects with normal renal function.
Dodatno, sistemska izloženost (AUCinf) slobodnom (ne-liposomalnom) MTP-PE u ispitanika s blagim do umjerenim oštećenjem bubrega bila je slična onoj opaženoj u zdravih odraslih ispitanika s normalnom funkcijom bubrega.
Additionally, there have been very rare reports of peripheral demyelinating polyneuropathies (including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, demyelinating polyneuropathy, and multifocal motor neuropathy).
Osim toga, vrlo je rijetko bilo prijava perifernih demijelinizirajućih polineuropatija (uključujući Guillan-Barréov sindrom, kroničnu upalnu demijelinizirajuću polineuropatiju, demijelinizirajuću polineuropatiju i multifokalnu motoričku neuropatiju).
Additionally, there is substantial number of events that are timely related to the initiation of treatment with agomelatine and with positive dechallenge.
Nadalje, postoji značajan broj slučajeva vremenski povezanih s početkom liječenja agomelatinom, u kojem je nuspojava prestala nakon prestanka uzimanje lijeka.
Additionally, TSH elevations were reported in 4 cytokine-refractory MRCC patients (2%).
Osim toga, povišene razine TSH-a prijavljene su u 4 bolesnika (2%) s MRCC-om refraktornim na citokine.
Additionally, twelve patients 13-17 years of age received posaconazole oral suspension 600 mg/day for prophylaxis of invasive fungal infections (Studies 316 and 1899).
Osim toga, 12 bolesnika u dobi od 13-17 godina primalo je posakonazol oralnu suspenziju u dozi od 600 mg na dan za profilaksu invazivnih gljivičnih infekcija (Ispitivanja 316 i 1899).
Additionally, Vogt-Koyanagi-Harada syndrome (an autoimmune inflammatory disorder affecting the eyes, skin and the membranes of the ears, brain and spinal cord), thoughts about threatening the life of others, mania (excessive or unreasonable enthusiasm), bipolar disorders (mood disorders characterized by alternating episodes of sadness and excitement), congestive heart failure, pericardial effusion (a fluid collection that develops between the pericardium (the lining of the heart) and the heart itself), and pulmonary fibrosis (scarring of the lungs) have been reported with IntronA use.
Pored navedenog, prilikom primjene lijeka IntronA prijavljena je pojava sindroma Vogt-Koyanagi- Harada (autoimuni upalni poremećaj koji zahvaća oči, kožu te ovojnice slušnog sustava, moždane ovojnice i ovojnice leđne moždine), razmišljanja o ugrožavanju života drugih ljudi, manija (pretjerano ili nerazumno oduševljenje), bipolarni poremećaji (poremećaji raspoloženja obilježeni naizmjeničnim epizodama tuge i uzbuđenja), kongestivno zatajenje srca, perikardijalni izljev (nakupljanje tekućine između perikarda (srčane ovojnice) i samog srca) i plućna fibroza (stvaranje ožiljaka na plućima).
Additionally, your doctor needs to inspect your head, your neck, your mouth, your lymph glands and you will undergo CT scans regularly.
Osim toga, liječnik Vam mora pregledati glavu, vrat, usnu šupljinu i limfne čvorove, a redovito ćete ići na snimanja CT-om.
Additionaly there have been post-marketing cases of dizziness, tremor, headache, somnolence, confusional state, hypertension, hallucinations and malaise.
Uz to, nakon stavljanja lijeka u promet bilo je slučajeva omaglice, tremora, glavobolje, somnolencije, stanja konfuzije, hipertenzije, halucinacije i malaksalosti.
Additionaly there have been post-marketing cases of dizziness, tremor, headache, somnolence, confusional state, hypertension, hallucinations and malaise.
Uz to, nakon stavljanja lijeka u promet bilo je slučajeva omaglice, tremora, glavobolje, somnolencije, stanja zbunjenosti, hipertenzije, halucinacije i malaksalosti.
Addmedica, 101 rue Saint Lazare – 75009 Paris - France
Addmedica, 101 rue Saint Lazare – 75009 Paris - Francuska
Address: Forellenweg 16
Adresa: Forellenweg 16
Address: Sumneytown Pike – PO Box 4 – West Point – Pennsylvania 19486 Country: United States of America
Adresa: Sumneytown Pike - PO Box 4-West Point Pennsylvania 19486 Zemlja: Sjedinjene Američke Države
Address: Waarderweg 39, 2031 BN Haarlem, P.O. Box 581, 2003 PC Haarlem Country: the Netherlands
Adresa: Waarderweg 39, 2031 BN Haarlem - P.O. BOX 581, 2003 PC Haarlem Zemlja: Nizozemska
Adefovir and Viramune may be coadministered without dose
Adefovir i Viramune se mogu
Adefovir and Viramune may be coadministered without dose
istodobno primjenjivati bez
Adefovir diphosphate selectively inhibits HBV DNA polymerases at concentrations 12-, 700-, and 10-fold lower than those needed to inhibit human DNA polymerases α, β, and γ, respectively.
Adefovir difosfat selektivno inhibira HBV DNK polimeraze u koncentracijama 12, 700 odnosno 10 puta nižim od onih koje su potrebne za inhibiciju humane DNK polimeraze α, β odnosno γ.
adefovir dipivoxil
adefovirdipivoksil.
Adefovir dipivoxil /Tenofovir disoproxil fumarate
Adefovirdipivoksil/ Tenofovirdizoproksilfumarat
Adefovir dipivoxil 10 mg roll over to tenofovir disoproxil
Adefovirdipivoksil 10 mg prebacivanje na tenofovirdizoproksil
Adefovir dipivoxil 10 mg roll over to tenofovir disoproxil 245 mg (as fumarate) n = 125
Adefovirdipivoksil 10 mg prebacivanje na tenofovirdizoproksil 245 mg (u obliku tenofovirdizoproksilfumarata) n = 125
Adefovir dipivoxil 10 mg roll over to tenofovir disoproxil 245 mg (as fumarate) n = 90
Adefovirdipivoksil 10 mg prebacivanje na tenofovirdizoproksil 245 mg (u obliku tenofovirdizoproksilfumarata) n = 90
Adefovir dipivoxil should not be administered concurrently with tenofovir disoproxil fumarate (Viread).
Adefovirdipivoksil se ne smije primjenjivati istovremeno s tenofovirdizoproksil fumaratom (Viread).
Adefovir is active against hepadnaviruses in vitro, including all common forms of lamivudine- resistant HBV (rtL180M, rtM204I, rtM204V, rtL180M/rtM204V), famciclovir-associated mutations (rtV173L, rtP177L, rtL180M, rtT184S or rtV207I) and hepatitis B immunoglobulin escape mutations (rtT128N and rtW153Q), and in in vivo animal models of hepadnavirus replication.
Adefovir je aktivan protiv hepadnavirusa in vitro, uključujući sve uobičajene oblike HBV-a rezistentnog na lamivudin (rtL180M,rtM204I, rtM204V, rtL180M/rtM204V), mutacije povezane s famciklovirom (rtV173L, rtP177L, rtL180M, rtT184S ili rtV207I) i mutacije koje izmiču (escape mutations) imunoglobulinima hepatitisa B (rtT128N i rtW153Q) te in vivo na životinjskim modelima replikacije hepadna virusa.
Adempas 0.5 mg – pack of 42 film-coated tablets - EU/1/13/907/001 Adempas 0.5 mg – pack of 84 film-coated tablets - EU/1/13/907/002 Adempas 0.5 mg – pack of 90 film-coated tablets - EU/1/13/907/003 Adempas 0.5 mg – pack of 294 film-coated tablets - EU/1/13/907/016 Adempas 1 mg – pack of 42 film-coated tablets - EU/1/13/907/004 Adempas 1 mg – pack of 84 film-coated tablets - EU/1/13/907/005 Adempas 1 mg – pack of 90 film-coated tablets - EU/1/13/907/006 Adempas 1 mg – pack of 294 film-coated tablets - EU/1/13/907/017 Adempas 1.5 mg – pack of 42 film-coated tablets - EU/1/13/907/007 Adempas 1.5 mg – pack of 84 film-coated tablets - EU/1/13/907/008 Adempas 1.5 mg – pack of 90 film-coated tablets - EU/1/13/907/009 Adempas 1.5 mg – pack of 294 film-coated tablets - EU/1/13/907/018 Adempas 2 mg – pack of 42 film-coated tablets - EU/1/13/907/010 Adempas 2 mg – pack of 84 film-coated tablets - EU/1/13/907/011 Adempas 2 mg – pack of 90 film-coated tablets - EU/1/13/907/012 Adempas 2 mg – pack of 294 film-coated tablets - EU/1/13/907/019 Adempas 2.5 mg – pack of 42 film-coated tablets - EU/1/13/907/013 Adempas 2.5 mg – pack of 84 film-coated tablets - EU/1/13/907/014 Adempas 2.5 mg – pack of 90 film-coated tablets - EU/1/13/907/015 Adempas 2.5 mg – pack of 294 film-coated tablets - EU/1/13/907/020
Adempas 0,5 mg – pakiranje s 42 filmom obložene tablete - EU/1/13/907/001 Adempas 0,5 mg – pakiranje s 84 filmom obložene tablete - EU/1/13/907/002 Adempas 0,5 mg – pakiranje s 90 filmom obloženih tableta - EU/1/13/907/003 Adempas 0,5 mg – pakiranje s 294 filmom obložene tablete - EU/1/13/907/016 Adempas 1 mg – pakiranje s 42 filmom obložene tablete - EU/1/13/907/004 Adempas 1 mg – pakiranje s 84 filmom obložene tablete - EU/1/13/907/005 Adempas 1 mg – pakiranje s 90 filmom obloženih tableta - EU/1/13/907/006 Adempas 1 mg – pakiranje s 294 filmom obložene tablete - EU/1/13/907/017 Adempas 1,5 mg – pakiranje s 42 filmom obložene tablete - EU/1/13/907/007 Adempas 1,5 mg – pakiranje s 84 filmom obložene tablete - EU/1/13/907/008 Adempas 1,5 mg – pakiranje s 90 filmom obloženih tableta - EU/1/13/907/009 Adempas 1,5 mg – pakiranje s 294 filmom obložene tablete - EU/1/13/907/018 Adempas 2 mg – pakiranje s 42 filmom obložene tablete - EU/1/13/907/010 Adempas 2 mg – pakiranje s 84 filmom obložene tablete - EU/1/13/907/011 Adempas 2 mg – pakiranje s 90 filmom obloženih tableta - EU/1/13/907/012 Adempas 2 mg – pakiranje s 294 filmom obložene tablete - EU/1/13/907/019 Adempas 2,5 mg – pakiranje s 42 filmom obložene tablete - EU/1/13/907/013 Adempas 2,5 mg – pakiranje s 84 filmom obložene tablete - EU/1/13/907/014 Adempas 2,5 mg – pakiranje s 90 filmom obloženih tableta - EU/1/13/907/015 Adempas 2,5 mg – pakiranje s 294 filmom obložene tablete - EU/1/13/907/020
Adempas 0.5 mg, 1 mg, 1.5 mg, 2 mg or 2.5 mg
Adempas 0,5 mg, 1 mg, 1,5 mg, 2 mg ili 2,5 mg
Adempas can be used on its own or in combination with other medicines for PAH called ‘endothelin receptor antagonists’.
Adempas se može koristiti samostalno ili u kombinaciji s drugim lijekovima za PAH naziva „antagonisti endotelinskih receptora“.
Adempas can only be obtained with a prescription and treatment should only be started and monitored by a doctor who has experience in the treatment of CTEPH or PAH.
Adempas se izdaje samo na liječnički recept, a liječenje treba započeti i pratiti liječnik iskusan u liječenju CTEPH-a ili PAH-a.
Adempas has been shown to be effective at improving the distance patients with CTEPH or PAH could walk in six minutes (a way of measuring exercise capacity):
Dokazano je da je Adempas djelotvoran u poboljšavanju udaljenosti u bolesnika sa CTEPH ili PAH, koji postići odgovarajući odgovor s obzirom na put prevaljen tijekom 6-minutnog hoda (način mjerenja kapaciteta vježbanja):
Adempas is a medicine that contains the active substance riociguat.
Adempas je lijek koji sadrži djelatnu tvar riociguat.
Adempas is available as tablets (0.5, 1, 1.5, 2 and 2.5 mg).
Adempas je dostupan kao tablete (0,5 mg, 1 mg, 1,5 mg, 2 mg i 2,5 mg).
Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with inoperable CTEPH, persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity (see section 5.1).
Adempas je indiciran za liječenje odraslih bolesnika funkcionalnog razreda II do III prema Svjetskoj zdravstvenoj organizaciji (SZO) s inoperabilnim KTEPH-om, perzistentnim ili recidivirajućim KTEPH-om nakon kirurškog liječenja, za poboljšanje tolerancije napora (vidjeti dio 5.1).
Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with inoperable CTEPH, persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity (see section 5.1).
Adempas je indiciran za liječenje odraslih bolesnika funkcionalnog razreda II do III prema Svjetskoj zdravstvenoj organizaciji (SZO) s inoperablinim KTEPH-om, perzistentnim ili recidivirajućim KTEPH-om nakon kirurškog liječenja, za poboljšanje tolerancije napora (vidjeti dio 5.1).
Adempas is only prescribed for certain forms of PAH, i.e. idiopathic PAH (the cause of PAH is unknown), heritable PAH and PAH caused by connective tissue disease.
Ademaps se propisuje samo za određene oblike PAH-a, odnosno za idiopatski PAH (uzrok PAH-a je nepoznat), nasljedni PAH i PAH uzrokovan bolešću vezivnog tkiva.
Adempas is used in patients with functional class II to III CTEPH or PAH.
Adempas se primjenjuje u bolesnika s funkcionalnim klasama II do III CTEPH ili PAH.
Adempas must not be used in patients with severely reduced liver function, with systolic blood pressure (blood pressure when the heart is contracting) below 95 mmHg before starting treatment, or during pregnancy.
Adempas se ne smije koristiti u bolesnika sa ozbiljno smanjenom funkcijom jetre, sa sistoličnim krvnim tlakom (krvni tlak pri kontrakciji srca) nižim od 95 mmHg prije početka liječenja ili tijekom trudnoće.
Adempas was compared with placebo (a dummy treatment) in one main study in 262 patients with CTEPH who could not be operated, or in whom CTEPH remained or returned after surgery.
Adempas je uspoređen s placebom (lažnim liječenjem) u jednom glavnom ispitivanju u 261 bolesnika oboljelih od CTEPH-a koji nisu mogli biti operirani ili u kojih je CTEPH bio perzistentan ili se vratio nakon kirurškog zahvata.
Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.
Adempas, kao monoterapija ili u kombinaciji s antagonistima endotelinskih receptora, je indiciran za liječenje odraslih bolesnika s plućnom arterijskom hipertenzijom (PAH) funkcionalnog razreda II do III prema SZO-u za poboljšanje tolerancije napora.
Adenocarcinoma (N=847)
Adenokarcinom
Adenosine receptor agonists including regadenoson can depress the sinoatrial (SA) and AV nodes and may cause first, second or third degree AV block, or sinus bradycardia.
Agonisti adenozinskih receptora uključujući regadenoson mogu deprimirati sinuatrijski (SA) i AV čvor i uzrokovati AV blok prvog, drugog i trećeg stupnja ili sinus bradikardiju.
Adenosine receptor agonists including regadenoson induce arterial vasodilation and hypotension.
Agonisti adenozinskih receptora uključujući regadenoson uzrokuju arterijsku vazodilataciju i hipotenziju.
Adenosine receptor agonists, including Rapiscan induce arterial vasodilation and hypotension.
Agonisti adenozinskih receptora uključujući Rapiscan izazivaju arterijsku vazodilataciju i hipotenziju.
Adenosine receptor agonists, including Rapiscan, can depress the SA and AV nodes and may cause first, second or third degree AV block, or sinus bradycardia requiring intervention.
Agonisti adenozinskih receptora uključujući Rapiscan mogu deprimirati SA i AV čvor i uzrokovati AV blok prvog, drugog i trećeg stupnja ili sinus bradikardiju koja zahtijeva intervenciju.
Adenosine receptor agonists, including Rapiscan, may cause bronchoconstriction and respiratory arrest (see section 4.8) , especially in patients with known or suspected bronchoconstrictive disease, chronic obstructive pulmonary disease (COPD) or asthma.
Agonisti adenozinskih receptora, uključujući Rapiscan, mogu uzrokovati bronhokonstrikciju i respiratorni zastoj (vidjeti dio 4.8), naročito u bolesnika s poznatom ili sa sumnjom na postojanje bronhokonstriktivne bolesti, kronične opstruktivne bolesti pluća (KOBP) ili astme.
Adenosine – Adenosine Agreement Rate (± SE)
adenozin – adenozin stopa podudarnosti (± SE)
Adenosine – Rapiscan Agreement Rate (± SE)
adenozin – Rapiscan stopa podudarnosti (± SE)
ADENURIC 120 mg film-coated tablets
ADENURIC 120 mg filmom obložene tablete
ADENURIC 120 mg tablets Febuxostat
ADENURIC 120 mg tablete febuksostat
ADENURIC 80 mg film-coated tablets
ADENURIC 80 mg filmom obložene tablete
ADENURIC 80 mg film-coated tablets ADENURIC 120 mg film-coated tablets Febuxostat
ADENURIC 80 mg filmom obložene tablete ADENURIC 120 mg filmom obložene tablete febuksostat
ADENURIC 80 mg tablets Febuxostat
ADENURIC 80 mg tablete febuksostat
ADENURIC is available as a 120 mg tablet.
Dostupne su tablete ADENURICA od 120 mg.
Adenuric is used in patients who already have signs of a build-up of crystals, including gouty arthritis (pain and inflammation in the joints) or tophi (‘stones’, larger deposits of urate crystals that can cause joint and bone damage).
Adenuric se koristi u bolesnika koji već pokazuju znakove nakupljanja kristala, uključujući urični artritis (bol i upala zglobova) ili tofi („kamenac”, veće nakupine kristala urata koje mogu izazvati oštećenje zglobova i kosti).
Adenuric is used to treat adults with long-term hyperuricaemia (high levels of uric acid or ‘urate’ in the blood).
Adenuric se koristi za liječenje odraslih osoba s dugotrajnom hiperuricemijom (visoka razina mokraćne kiseline ili „urata” u krvi).
ADENURIC should not be used during pregnancy.
ADENURIC se ne smije uzimati tijekom trudnoće.
ADENURIC tablets contain the active substance febuxostat and are used to treat gout, which is associated with an excess of a chemical called uric acid (urate) in the body.
ADENURIC tablete sadrže djelatnu tvar febuksostat i koriste se za liječenje uloga (gihta), uzrokovanih povećanim nakupljanjem tvari koja se zove mokraćna kiselina (urati) u organizmu.
Adequate calcium and vitamin D intake are recommended in association with Aclasta administration
Preporučuje se odgovarajući unos kalcija i vitamina D uz primjenu Aclaste
Adequate calcium and vitamin D intake are recommended in association with zoledronic acid administration
Preporučuje se odgovarajući unos kalcija i vitamina D uz primjenu zoledronatne kiseline
Adequate calcium and vitamin D intake are recommended in association with Zoledronic acid Teva Pharma administration.
Uz primjenu Zoledronatne kiseline Teva Pharma, preporučuje se odgovarajući unos kalcija i vitamina
Adequate care and precautions should be taken in the disposal of items (syringes, needles, etc.) used to reconstitute and/or dilute cytotoxic medicinal products.
Potrebno je poduzeti odgovarajuće mjere opreza pri zbrinjavanju predmeta (štrcaljki, igala i dr.) korištenih za rekonstituciju i/ili razrjeđivanje citotoksičnih lijekova.